Oppenheimer raised the firm’s price target on DexCom to $150 from $135 and keeps an Outperform rating on the shares. DexCom’s Q2 sales beat the Street’s estimates led by solid OUS performance on share gains G7/Dexcom ONE, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DXCM: